Pdt Partners, LLC Satsuma Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $62,250 - $93,600	-15,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $111,343 - $175,844	-24,525 Reduced 62.05%	15,000 $70,000
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $98,232 - $148,371	-20,465 Reduced 34.11%	39,525 $279,000
Q1 2021 May 17, 2021	SELL	$4.57 - $7.18 $32,492 - $51,049	-7,110 Reduced 10.6%	59,990 $355,000
Q4 2020 Feb 16, 2021	BUY	$3.56 - $5.09 $181,314 - $259,238	50,931 Added 314.99%	67,100 $309,000
Q3 2020 Nov 16, 2020	BUY	$3.85 - $28.47 $62,250 - $460,331	16,169 New	16,169 $63,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.